Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung PK of Model Drugs via ELF Sampling
NCT03524066Completed
- Sponsor
- Fraunhofer ITEM
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of salbutamol, salmeterol, fluticasone propionate nasal spray and propranolol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Fraunhofer ITEM. Primary endpoints: Maximum concentration of Salbutamol in the lung at 24.5 hours, Maximum concentration of Salmeterol in the lung at 24.5 hours and 2 more. Started Apr 2018; status: completed.
02
Drugs
salbutamolsalmeterolfluticasone propionate nasal spraypropranolol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03524066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524066.